Unique ID issued by UMIN | UMIN000050746 |
---|---|
Receipt number | R000057801 |
Scientific Title | Efficacy and safety of high-intensity, low-frequency expiratory pressure load training in patients with chronic obstructive pulmonary disease |
Date of disclosure of the study information | 2023/04/03 |
Last modified on | 2023/04/01 18:17:21 |
Efficacy and safety of high-intensity, low-frequency expiratory pressure load training in patients with chronic obstructive pulmonary disease
HILF-EPT study
Efficacy and safety of high-intensity, low-frequency expiratory pressure load training in patients with chronic obstructive pulmonary disease
HILF-EPT study
Japan |
Chronic obstructive pulmonary disease
Pneumology |
Others
NO
To investigate the efficacy and safety of high-intensity, low-frequency expiratory pressure load training (EPT) for 12 weeks in patients with chronic obstructive pulmonary disease (COPD) suffering from progressive external dyspnea.
Safety,Efficacy
Change of the 6-min walk distance and the increase in the modified Borg scale at 12 weeks.
Respiratory muscle pressure, CAT, NRADL, body composition, handgrip strength, five times sit-to-stand test.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Maneuver |
The patients will receive standard pulmonary rehabilitation in addition to EPT 30 times (5 times x 6 sets) per day, 3 days a week for 12 weeks. There is a 1 minute interval between each set, and the patients have at least one rest day after training day. The load of EPT will be increased to 60-80% of the maximum expiratory pressure, which will be adjusted at 6 week.
40 | years-old | <= |
Not applicable |
Male and Female
1) Patients with COPD diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
2) Patients underwent pulmonary rehabilitation, but complaining of progressive external dyspnea.
3) Patients whose conditions are stable and who are able to tolerate the 6-min walk test to ensure adequate evaluation.
4) Patients provided written informed consent to participate in this study.
1) Patients with active infection.
2) Patients with severe heart disease.
3) Patients whose drug regimen was changed during this study.
4) Patients with a high risk of developing pneumothorax.
5) In addition to the above exclusion criteria, patients judged by their physician to be ineligible to participate in this study.
5
1st name | Masaru |
Middle name | |
Last name | Yanai |
Japanese Red Cross Ishinomaki Hospital
Department of Respiratory Medicine
986-8522
71 Nishimichishita, Hebita, Ishinomaki, Miyagi, Japan
0225-21-7220
myan_2@hotmail.com
1st name | Seiichi |
Middle name | |
Last name | Kobayashi |
Japanese Red Cross Ishinomaki Hospital
Department of Respiratory Medicine
986-8522
71 Nishimichishita, Hebita, Ishinomaki, Miyagi, Japan
0225-21-7220
skoba-thk@umin.ac.jp
Japanese Red Cross Ishinomaki Hospital
Japanese Red Cross Ishinomaki Hospital
Self funding
Ishinomaki COPD Network(ICON)
The Ethics Committee of Japanese Red Cross Ishinomaki Hospital
71 Nishimichishita, Hebita, Ishinomaki, Miyagi, Japan
0225-21-7220
i-hosp@ishinomaki.jrc.or.jp
NO
石巻赤十字病院(宮城県)、斎藤病院(宮城県)
2023 | Year | 04 | Month | 03 | Day |
Unpublished
Enrolling by invitation
2023 | Year | 03 | Month | 06 | Day |
2023 | Year | 03 | Month | 28 | Day |
2023 | Year | 04 | Month | 03 | Day |
2026 | Year | 03 | Month | 30 | Day |
2023 | Year | 04 | Month | 01 | Day |
2023 | Year | 04 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000057801